Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

SynPred: Prediction of Drug Combination Effects in Cancer using Full-Agreement Synergy Metrics and Deep Learning

Version 1 : Received: 13 April 2021 / Approved: 14 April 2021 / Online: 14 April 2021 (17:44:40 CEST)

How to cite: Preto, A.J.; Matos-Filipe, P.; Mourão, J.; Moreira, A.I.S. SynPred: Prediction of Drug Combination Effects in Cancer using Full-Agreement Synergy Metrics and Deep Learning. Preprints 2021, 2021040395 (doi: 10.20944/preprints202104.0395.v1). Preto, A.J.; Matos-Filipe, P.; Mourão, J.; Moreira, A.I.S. SynPred: Prediction of Drug Combination Effects in Cancer using Full-Agreement Synergy Metrics and Deep Learning. Preprints 2021, 2021040395 (doi: 10.20944/preprints202104.0395.v1).

Abstract

High-throughput screening technologies continues to produce large amounts of multiomics data from different populations and cell types for various diseases, such as cancer. However, analysis of such data encounters difficulties due to cancer heterogeneity, further exacerbated by human biological complexity and genomic variability. There is a need to redefine the drug discovery development pipeline, bringing an Artificial Intelligence (AI)-powered informational view that integrates relevant biological information and explores new ways to develop effective anticancer approaches. Here, we show SynPred, an interdisciplinary approach that leverages specifically designed ensembles of AI-algorithms, links omics and biophysical traits to predict synergistic anticancer drug synergy. SynPred exhibits state-of-the-art performance metrics: accuracy – 0.85, precision – 0.77, recall – 0.75, AUROC – 0.82, and F1-score - 0.76 in an independent test set. Moreover, data interpretability was achieved by deploying the most current and robust feature importance approaches. A simple web-based application available online at http://www.moreiralab.com/resources/synpred/ was constructed to predict synergistic anticancer drug combinations requiring only the upload of the two drug SMILES to be tested, allowing easy access by non-expert researchers.

Subject Areas

Deep-Learning; Interpretability; Omics; Biophysics; Drug Synergy; Cancer

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.